Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Theodor Dingermann & Florian Scotte. (2016) Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience. Expert Opinion on Biological Therapy 16:7, pages 967-974.
Read now
Read now
Ashraf Mikhail & Christopher Brown. (2015) Clinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta. Biosimilars 5, pages 65-73.
Read now
Read now
Mary Lynn Davis-Ajami, Jun Wu, Katherine Downton, Emilie Ludeman & Virginia Noxon. (2014) Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics: Targets and Therapy 8, pages 155-167.
Read now
Read now
Alaa Bagalagel, Abdulaziz Mohammed, Karen MacDonald & Ivo Abraham. (2013) Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars 3, pages 35-43.
Read now
Read now
Qingqiao Tan, Qingcheng Guo, Chen Fang, Chong Wang, Bohua Li, Hao Wang, Jing Li & Yajun Guo. (2012) Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. mAbs 4:6, pages 761-774.
Read now
Read now
Hans C Ebbers, Michael Muenzberg & Huub Schellekens. (2012) The safety of switching between therapeutic proteins. Expert Opinion on Biological Therapy 12:11, pages 1473-1485.
Read now
Read now
Ivo Abraham & Karen MacDonald. (2012) Clinical safety of biosimilar recombinant human erythropoietins. Expert Opinion on Drug Safety 11:5, pages 819-840.
Read now
Read now
B. Gertz, P. Kes, A. Essaian, P. Bias, A. Buchner & D. Zellner. (2012) Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research and Opinion 28:7, pages 1101-1110.
Read now
Read now
Wolfgang Jelkmann. (2012) Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments. Expert Opinion on Biological Therapy 12:5, pages 581-592.
Read now
Read now
B. Gertz, E. Kohler, P. Kes, A. Essaian, P. Bias, A. Buchner & R. Elsässer. (2010) Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research and Opinion 26:10, pages 2393-2402.
Read now
Read now
Lei Lei & Kurt Olson. (2009) Evaluating Statistical Methods to Establish Clinical Similarity of Two Biologics. Journal of Biopharmaceutical Statistics 20:1, pages 62-74.
Read now
Read now
Stefan Krivoshiev, Vasil V. Todorov, Jacek Manitius, Stanislaw Czekalski, Paul Scigalla & Rossen Koytchev. (2008) Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Current Medical Research and Opinion 24:5, pages 1407-1415.
Read now
Read now
Articles from other publishers (54)
Edmund YM Chung, Suetonia C Palmer, Valeria M Saglimbene, Jonathan C Craig, Marcello Tonelli & Giovanni FM Strippoli. (2023) Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2023:2.
Crossref
Crossref
Norihiro Nishioka, Yan Luo, Takuya Taniguchi, Tsuyoshi Ohnishi, Miho Kimachi, Roland CK Ng & Norio Watanabe. (2022) Carnitine supplements for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews 2022:12.
Crossref
Crossref
Bolong Miao, Alina Nikolaevna Isachkina, Evgeny Viktorovich Shutov, Alexander Alekseevich Selyutin, Lyudmila Vladimirovna Kvitkova, Valery Yuryevich Shilo, Olga Nikolaevna Vetchinnikova, Ilya Vyacheslavovich Alexandrov, Dmitry Vladislavovich Perlin, Alexander Vasilievich Zuev, Igor Leonidovich Davydkin, Tatyana Pavlovna Mironova, Olga Mikhailovna Solovyova, Alexey Pavlovich Tutin, Alexey Mikhailovich Omelchenko, Kriengsak Vareesangthip, Nadezhda Georgievna Khadikova, Man Li & Xiang Li. (2022) Biosimilar erythropoietin in anemia treatment (BEAT)—Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. Medicine 101:47, pages e31426.
Crossref
Crossref
Sarfaraz K. Niazi. (2022)
No two classes of biosimilars: Urgent advice to the US Congress and the
FDA
. Journal of Clinical Pharmacy and Therapeutics.
Crossref
Crossref
Liese Barbier, Steven Simoens, Arnold G. Vulto & Isabelle Huys. (2020) European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice. BioDrugs 34:6, pages 797-808.
Crossref
Crossref
Liese Barbier, Hans C. Ebbers, Paul Declerck, Steven Simoens, Arnold G. Vulto & Isabelle Huys. (2020) The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clinical Pharmacology & Therapeutics 108:4, pages 734-755.
Crossref
Crossref
Efraín Esteban, Rosa-Helena Bustos, Julio-César García & Edwin Jáuregui. (2019) Biosimilars: An Approach to some Current Worldwide Regulation Frameworks. Current Clinical Pharmacology 14:1, pages 16-40.
Crossref
Crossref
June M. McKoy & Frank J. Giles. 2019. Cancer Policy: Pharmaceutical Safety. Cancer Policy: Pharmaceutical Safety
61
73
.
M. Aapro, Y. Beguin, C. Bokemeyer, M. Dicato, P. Gascón, J. Glaspy, A. Hofmann, H. Link, T. Littlewood, H. Ludwig, A. Österborg, P. Pronzato, V. Santini, D. Schrijvers, R. Stauder, K. Jordan & J. Herrstedt. (2018) Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology 29, pages iv96-iv110.
Crossref
Crossref
Steven Fishbane, Bhupinder Singh, Seema Kumbhat, Wayne A. Wisemandle & Nancy E. Martin. (2018) Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. Clinical Journal of the American Society of Nephrology 13:8, pages 1204-1214.
Crossref
Crossref
Giovanna Stoppa, Carmen D’Amore, Anita Conforti, Giuseppe Traversa, Mauro Venegoni, Maurizio Taglialatela & Roberto Leone. (2018) Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study. BioDrugs 32:4, pages 367-375.
Crossref
Crossref
David Goldsmith, Frank Dellanna, Martin Schiestl, Andriy Krendyukov & Christian Combe. (2018) Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?. Clinical Drug Investigation 38:6, pages 481-490.
Crossref
Crossref
Domenico Motola, Alberto Vaccheri, Andrea Roncadori, Monia Donati, Giulia Bonaldo, Anna Covezzoli, Piera Polidori & Stefano Bianchi. (2018) Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology. European Journal of Clinical Pharmacology 74:6, pages 805-810.
Crossref
Crossref
Ross A. McKinnon, Matthew Cook, Winston Liauw, Mona Marabani, Ian C. Marschner, Nicolle H. Packer & Johannes B. Prins. (2018) Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. BioDrugs 32:1, pages 27-52.
Crossref
Crossref
Paul Cornes & Matti Aapro. (2018) The Impact of Biosimilars in Supportive Care in Cancer. European Oncology & Haematology 14:1, pages 20.
Crossref
Crossref
Jagannath H. Saikumar & Csaba P. Kovesdy. 2018. Management of Anemia. Management of Anemia
81
112
.
Roberto Minutolo, Piergiorgio Bolasco, Paolo Chiodini, Stefano Sposini, Maurizio Borzumati, Cataldo Abaterusso, Alessandra A. Mele, Domenico Santoro, Valeria Canale, Alberto Santoboni, Oliviero Filiberti, Fulvio Fiorini, Carlo Mura, Patrizio Imperiali, Silvio Borrelli, Luigi Russo, Luca De Nicola & Domenico Russo. (2017) Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients. Clinical Drug Investigation 37:10, pages 965-973.
Crossref
Crossref
Won Park, Chang-Hee Suh, Seung Cheol Shim, Francisco Fidencio Cons Molina, Slawomir Jeka, Francisco G. Medina-Rodriguez, Pawel Hrycaj, Piotr Wiland, Eun Young Lee, Pavel Shesternya, Volodymyr Kovalenko, Leysan Myasoutova, Marina Stanislav, Sebastiao Radominski, Mie Jin Lim, Jung-Yoon Choe, Sang Joon Lee, Sung Young Lee, Sung Hwan Kim & Dae Hyun Yoo. (2017) Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. BioDrugs 31:4, pages 369-377.
Crossref
Crossref
Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, Pedro Miranda, Edgar Ramiterre, Allan Lanzon, Asta Baranauskaite, Piotr Wiland, Carlos Abud-Mendoza, Boycho Oparanov, Svitlana Smiyan, HoUng Kim, Sang Joon Lee, SuYeon Kim & Won Park. (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Annals of the Rheumatic Diseases 76:2, pages 355-363.
Crossref
Crossref
Won Park, Dae Hyun Yoo, Pedro Miranda, Marek Brzosko, Piotr Wiland, Sergio Gutierrez-Ureña, Helena Mikazane, Yeon-Ah Lee, Svitlana Smiyan, Mie-Jin Lim, Vladimir Kadinov, Carlos Abud-Mendoza, HoUng Kim, Sang Joon Lee, YunJu Bae, SuYeon Kim & Jürgen Braun. (2017) Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Annals of the Rheumatic Diseases 76:2, pages 346-354.
Crossref
Crossref
Marianne Heibert Arnlind, Linda Fryklund, Sigurd Vitols & Göran Bertilsson. (2016) Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review. European Journal of Clinical Pharmacology 72:10, pages 1161-1169.
Crossref
Crossref
H. A. Dowlat, M. K. Kuhlmann, H. Khatami & F. J. Ampudia-Blasco. (2016) Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes, Obesity and Metabolism 18:8, pages 737-746.
Crossref
Crossref
Amit B. Agarwal & Ali McBride. (2016) Understanding the biosimilar approval and extrapolation process—A case study of an epoetin biosimilar. Critical Reviews in Oncology/Hematology 104, pages 98-107.
Crossref
Crossref
Roberto Minutolo, Maurizio Borzumati, Stefano Sposini, Cataldo Abaterusso, Gianni Carraro, Alberto Santoboni, Carlo Mura, Oliviero Filiberti, Domenico Santoro, Romano Musacchio, Patrizio Imperiali, Fulvio Fiorini, Luca De Nicola & Domenico Russo. (2016) Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients. American Journal of Kidney Diseases 68:1, pages 170-172.
Crossref
Crossref
Jürgen Braun & Alex Kudrin. (2016) Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals 44:4, pages 257-266.
Crossref
Crossref
Ylenia Ingrasciotta, Francesco Giorgianni, Ilaria Marcianò, Jenny Bolcato, Roberta Pirolo, Alessandro Chinellato, Valentina Ientile, Domenico Santoro, Armando A. Genazzani, Angela Alibrandi, Andrea Fontana, Achille P. Caputi & Gianluca Trifirò. (2016) Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. PLOS ONE 11:5, pages e0155805.
Crossref
Crossref
Majed Khraishi, David Stead, Milan Lukas, Florian Scotte & Holger Schmid. (2016) Biosimilars: A Multidisciplinary Perspective. Clinical Therapeutics 38:5, pages 1238-1249.
Crossref
Crossref
Carlo Genova, Erika Rijavec & Francesco Grossi. (2016) Hematopoietic growth factors in lung cancer. Current Opinion in Oncology 28:2, pages 135-144.
Crossref
Crossref
Liem Andhyk Halim, Vera Brinks, Wim Jiskoot, Stefan Romeijn, Rob Haselberg, Chris Burns, Meenu Wadhwa & Huub Schellekens. (2016) Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. Journal of Pharmaceutical Sciences 105:2, pages 542-550.
Crossref
Crossref
Dong Il Park. (2016) Current status of biosimilars in the treatment of inflammatory bowel diseases. Intestinal Research 14:1, pages 15.
Crossref
Crossref
Matthew J Renwick, Kate Smolina, Emilie J Gladstone, Deirdre Weymann & Steven G Morgan. (2016) Postmarket policy considerations for biosimilar oncology drugs. The Lancet Oncology 17:1, pages e31-e38.
Crossref
Crossref
Jorge Coronado Daza, Arturo J Martí-Carvajal, Amaury Ariza García, Joaquín Rodelo Ceballos, Nancy Yomayusa González, Carol Páez-Canro, César Loza Munárriz & Gerard Urrútia. (2015) Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref
Steven Jarrett & Theodor Dingermann. (2015) Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars. Hospital Pharmacy 50:10, pages 884-893.
Crossref
Crossref
Adrian Covic & Ivo Abraham. (2015) State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. International Urology and Nephrology 47:9, pages 1529-1539.
Crossref
Crossref
Steven Fishbane & Hitesh H. Shah. (2015) The Emerging Role of Biosimilar Epoetins in Nephrology in the United States. American Journal of Kidney Diseases 65:4, pages 537-542.
Crossref
Crossref
Paul Wilson & Cheryl Wood. (2015) BIOSIMILAR ESAS: A COMPARATIVE REVIEW. Journal of Renal Care 41:1, pages 53-61.
Crossref
Crossref
Natasha Irrera, Alessandra Bitto, Gabriele Pizzino, Mario Vaccaro, Francesco Squadrito, Mariarosaria Galeano, Francesco Stagno d’Alcontres, Ferdinando Stagno d’Alcontres, Michele Buemi, Letteria Minutoli, Michele Rosario Colonna & Domenica Altavilla. (2015) Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury. BioMed Research International 2015, pages 1-9.
Crossref
Crossref
Suetonia C Palmer, Valeria Saglimbene, Dimitris Mavridis, Georgia Salanti, Jonathan C Craig, Marcello Tonelli, Natasha Wiebe & Giovanni FM Strippoli. (2014) Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Jay B. Wish. (2014) The Approval Process for Biosimilar Erythropoiesis-Stimulating Agents. Clinical Journal of the American Society of Nephrology 9:9, pages 1645-1651.
Crossref
Crossref
Ivo Abraham, Lucy Han, Diana Sun, Karen MacDonald & Matti Aapro. (2014) Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncology 10:9, pages 1599-1609.
Crossref
Crossref
Tibor Hlavaty & Juraj Letkovsky. (2014) Biosimilars in the therapy of inflammatory bowel diseases. European Journal of Gastroenterology & Hepatology 26:6, pages 581-587.
Crossref
Crossref
Lászlo Tóthfalusi, László Endrényi & Shein-Chung Chow. (2014) Statistical and regulatory considerations in assessments of interchangeability of biological drug products. The European Journal of Health Economics 15:S1, pages 5-11.
Crossref
Crossref
Judith Genevieve Marin, Marianna Leung, Clifford Lo, Nicole W Tsao & Daniel J Martinusen. (2014) Efficacy and Safety Data of Subsequent Entry Biologics Pertinent to Nephrology Practice: A Systematic Review. Canadian Journal of Kidney Health and Disease 1, pages 34.
Crossref
Crossref
Franziska Hörbrand, Peter Bramlage, Johann Fischaleck, Joerg Hasford & Reinhard Brunkhorst. (2012) A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. European Journal of Clinical Pharmacology 69:4, pages 929-936.
Crossref
Crossref
Walter H. Hörl. (2013) Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease. Drugs 73:2, pages 117-130.
Crossref
Crossref
Ashraf Mikhail & Mourad Farouk. (2012) Epoetin Biosimilars in Europe: Five Years On. Advances in Therapy 30:1, pages 28-40.
Crossref
Crossref
Cornelius F. Waller. (2012) Biosimilars and their use in hematology and oncology. Community Oncology 9:6, pages 198-205.
Crossref
Crossref
Islah Ahmed, Ben Kaspar & Uma Sharma. (2012) Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States. Clinical Therapeutics 34:2, pages 400-419.
Crossref
Crossref
Gerhard Lonnemann & Eike Wrenger. (2012) Biosimilar Epoetin Zeta in Nephrology: Effect of Injection Frequency on Weekly Dose. International Journal of Clinical Medicine 03:07, pages 598-602.
Crossref
Crossref
Andrzej Więcek, Islah Ahmed, Paul Scigalla & Rossen Koytchev. (2010) Switching epoetin alfa and epoetin zeta in patients with Renal Anemia on Dialysis: Posthoc analysis. Advances in Therapy 27:12, pages 941-952.
Crossref
Crossref
D. Verhelst. (2010) Actualités dans la prise en charge de l’anémie Congrès mondial de Néphrologie 2009. Néphrologie & Thérapeutique 6:1, pages 1-9.
Crossref
Crossref
Stefan Krivoshiev, Volker Wizemann, Stanisław Czekalski, Adalbert Schiller, Steva Plješa, Michael Wolf-Pflugmann, Marianne Siebert-Weigel, Rossen Koytchev & Angelika Bronn. (2010) Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Advances in Therapy 27:2, pages 105-117.
Crossref
Crossref
Stefan E. Franz. (2009) Erythropoiesis‐stimulating agents: development, detection and dangers. Drug Testing and Analysis 1:6, pages 245-249.
Crossref
Crossref
Conrad Baldamus, Stefan Krivoshiev, Michael Wolf-Pflugmann, Marianne Siebert-Weigel, Rossen Koytchev & Angelika Bronn. (2008) Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Advances in Therapy 25:11, pages 1215-1228.
Crossref
Crossref